On December 22, the U.S. Food and Drug Administration (FDA) granted accelerated approval to mosunetuzumab-axgb for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma after two or more lines of systemic therapy.
For more information, read Genetech's new release.
Posted 12/23/2022
In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.
